WO1990012101A1 - Vaccinia vectors, vaccinia genes and expression products thereof - Google Patents
Vaccinia vectors, vaccinia genes and expression products thereof Download PDFInfo
- Publication number
- WO1990012101A1 WO1990012101A1 PCT/GB1990/000493 GB9000493W WO9012101A1 WO 1990012101 A1 WO1990012101 A1 WO 1990012101A1 GB 9000493 W GB9000493 W GB 9000493W WO 9012101 A1 WO9012101 A1 WO 9012101A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sal
- vaccinia virus
- vaccinia
- dna
- sequences
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 180
- 239000013598 vector Substances 0.000 title claims abstract description 22
- 206010046865 Vaccinia virus infection Diseases 0.000 title claims description 50
- 208000007089 vaccinia Diseases 0.000 title claims description 48
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 92
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 86
- 239000002773 nucleotide Substances 0.000 claims abstract description 52
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 52
- 108020004414 DNA Proteins 0.000 claims abstract description 50
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 44
- 230000003612 virological effect Effects 0.000 claims abstract description 14
- 238000003780 insertion Methods 0.000 claims abstract description 11
- 230000037431 insertion Effects 0.000 claims abstract description 11
- 230000035772 mutation Effects 0.000 claims abstract description 6
- 108010061982 DNA Ligases Proteins 0.000 claims description 67
- 102000012410 DNA Ligases Human genes 0.000 claims description 56
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 56
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 37
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 18
- 229960005486 vaccine Drugs 0.000 claims description 13
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 8
- 206010062016 Immunosuppression Diseases 0.000 claims description 7
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 7
- 230000001506 immunosuppresive effect Effects 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000005847 immunogenicity Effects 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 108700028369 Alleles Proteins 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 241000700605 Viruses Species 0.000 description 84
- 235000018102 proteins Nutrition 0.000 description 82
- 210000004027 cell Anatomy 0.000 description 65
- 235000001014 amino acid Nutrition 0.000 description 45
- 239000012634 fragment Substances 0.000 description 45
- 229940024606 amino acid Drugs 0.000 description 44
- 150000001413 amino acids Chemical class 0.000 description 32
- 102000004190 Enzymes Human genes 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 31
- 229940088598 enzyme Drugs 0.000 description 31
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 29
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 29
- 208000015181 infectious disease Diseases 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 20
- 102000006601 Thymidine Kinase Human genes 0.000 description 19
- 108020004440 Thymidine kinase Proteins 0.000 description 19
- 108020004999 messenger RNA Proteins 0.000 description 18
- 239000000284 extract Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 14
- 241000700584 Simplexvirus Species 0.000 description 12
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 102000019197 Superoxide Dismutase Human genes 0.000 description 11
- 108010012715 Superoxide dismutase Proteins 0.000 description 11
- 230000029812 viral genome replication Effects 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 108010087819 Fc receptors Proteins 0.000 description 7
- 102000009109 Fc receptors Human genes 0.000 description 7
- 108090001090 Lectins Proteins 0.000 description 7
- 102000004856 Lectins Human genes 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002523 lectin Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 241000701533 Escherichia virus T4 Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 101100366942 Mus musculus Ston1 gene Proteins 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 101900202134 Vaccinia virus DNA ligase Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100037357 Thymidylate kinase Human genes 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 5
- 108010000742 dTMP kinase Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 108091033380 Coding strand Proteins 0.000 description 4
- 102000006912 Complement C4b-Binding Protein Human genes 0.000 description 4
- 108010047548 Complement C4b-Binding Protein Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000238556 Megabalanus rosa Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 101000748061 Acholeplasma phage L2 Uncharacterized 16.1 kDa protein Proteins 0.000 description 3
- 241000701386 African swine fever virus Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 101000947615 Clostridium perfringens Uncharacterized 38.4 kDa protein Proteins 0.000 description 3
- 102100029058 Coagulation factor XIII B chain Human genes 0.000 description 3
- 101710142646 Coagulation factor XIII B chain Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000004381 Complement C2 Human genes 0.000 description 3
- 108090000955 Complement C2 Proteins 0.000 description 3
- 108010053085 Complement Factor H Proteins 0.000 description 3
- 102100035432 Complement factor H Human genes 0.000 description 3
- 102100029995 DNA ligase 1 Human genes 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 101000964391 Enterococcus faecalis UPF0145 protein Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000748063 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 11.1 kDa protein in rep-hol intergenic region Proteins 0.000 description 3
- 241000276570 Hemitripterus Species 0.000 description 3
- 101000790840 Klebsiella pneumoniae Uncharacterized 49.5 kDa protein in cps region Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000002528 anti-freeze Effects 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008238 biochemical pathway Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 108010060248 DNA Ligase ATP Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- UJLXYODCHAELLY-XLPZGREQSA-N dTDP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 UJLXYODCHAELLY-XLPZGREQSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940080469 phosphocellulose Drugs 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- KSJBMDCFYZKAFH-UHFFFAOYSA-N 2-(2-sulfanylethylsulfanyl)ethanethiol Chemical compound SCCSCCS KSJBMDCFYZKAFH-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-FOEKBKJKSA-N 3654-96-4 Chemical compound C[35S]CC[C@H](N)C(O)=O FFEARJCKVFRZRR-FOEKBKJKSA-N 0.000 description 1
- 102000021527 ATP binding proteins Human genes 0.000 description 1
- 108091011108 ATP binding proteins Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 101710184994 Complement control protein Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910017518 Cu Zn Inorganic materials 0.000 description 1
- 229910017752 Cu-Zn Inorganic materials 0.000 description 1
- 229910017943 Cu—Zn Inorganic materials 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001027052 Homo sapiens Thymidylate kinase Proteins 0.000 description 1
- 101000800463 Homo sapiens Transketolase Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010014691 Lithostathine Proteins 0.000 description 1
- 102100027361 Lithostathine-1-alpha Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102100040307 Protein FAM3B Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- IGWHDMPTQKSDTL-JXOAFFINSA-N TMP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JXOAFFINSA-N 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 101710134973 Uncharacterized 9.7 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 241000700646 Vaccinia virus WR Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229940105784 coagulation factor xiii Drugs 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229940124954 vaccinia virus vaccine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to recombinant vaccinia virus vectors.
- it relates to the attenuation of the virus, to potential enhanced immunogenicity of the virus, to the provision of sites for the insertion of heterologous gene sequences into the virus, and to the use of the recombinant virus vectors thereby provided.
- It also relates to proteins which are the expression products of vaccinia genes. DESCRIPTION OF PRIOR ART Live vaccinia virus was used as the vaccine to immunise against, and eradicate smallpox.
- Vaccinia virus is the prototypical member of the poxvirus family and therefore it has been extensively studied. It is a large DNA-containing virus which replicates in the cytoplasm of the host cell.
- the linear double-stranded genome of approximately 185,000 base pairs has the potential to encode at least 200 proteins (Moss, B. (1985) In B.N. Fields, D.M. Knipe, J.L. Melnick, R.M. Channock, B.R. Roizman and R.E. Shope (eds.), Virology. Raven Press, New York, pp. 685-704).
- the cytoplasmic site of replication requires that vaccinia virus encodes many enzymes and protein factors necessary for DNA synthesis. Advances in molecular genetics have made possible the construction of recombinant vaccinia viruses that contain and express genes derived from other organisms (for review see Mackett, M. & Smith G.L. (1986), J. Gen.
- the recombinant viruses retain their infectivity and express the foreign gene (or genes) during the normal replicative cycle of the virus. Immunisation of animals with the recombinant viruses has resulted in specific immune responses against the protein(s) expressed by the vaccinia virus, including those protein(s) expressed by the foreign gene(s) and in several cases has conferred protection against the pathogenic organism from which the foreign gene was derived.
- Recombinant vaccinia viruses have, therefore, potential application as new live vaccines in human or veterinary medicine.
- Advantages of this type of new vaccine include the low cost of vaccine manufacture and administration (because the virus is self-replicating), the induction of both humeral and cell-mediated immune responses, the stability of the viral vaccine without refrigeration and the practicality of inserting multiple foreign gengs from different organisms into vaccinia virus, to construct polyvalent vaccines effective against multiple pathogens.
- a disadvantage of this approach is the re ⁇ use of a virus vaccine that has been recognised as causing rare vaccine-related complications. The applicants have now identified unobvious gene sequences which may be deleted from the viral genome.
- the applicants propose that part or all of one or more of these gene sequences may be deleted from the viral genome to allow (i) greater attenuation of the virus; and/or (ii) enhancement of immunogenicity of recombinant vaccinia virus; and/or (iii) further gene sequence insertion sites so that more foreign DNA may be included in the virus.
- the gene sequences are essential for viral replication, viral attenuation can still be effected by altering the gene product (e.g. by manipulation at gene level) such that a protein function affecting pathogenicity is adversely affected whilst keeping the protein functional for virus application.
- a vaccinia virus vector wherein a) part or all of one or more of the following nucleotide sequences is deleted from the viral genome; and/or b) one or more of said nucleotide sequences is inactivated by mutation or the insertion of foreign DNA; and/or c) one or more of said nucleotide sequences is changed to alter the function of a protein product encoded by said nucleotide sequence; which nucleotide sequences are sequences designated herein as i) Sal F 3R, ii) Sal F 9R, iii) Sal F 13R, iv) B5R, v) Sal F 15R.
- DNA sequences encoding one or more heterologous polypeptides may be incorporated in the viral genome.
- the DNA sequences encoding the heterologous peptides may be inserted into one or more ligation sites created by the deletion or deletions from the viral genome.
- the recombinant vaccinia viruses of the present invention have the potential for enhanced immunogenicity. This may result from either the deletion of vaccinia genes which cause immunosuppression (e.g. the complement homologue and the human FcR for IgE) or by insertion of a gene which potentiates the immune response (e.g. expressing the authentic CD23 gene in vaccinia virus).
- vaccinia genes which cause immunosuppression e.g. the complement homologue and the human FcR for IgE
- a gene which potentiates the immune response e.g. expressing the authentic CD23 gene in vaccinia virus.
- the present invention provides a vaccinia virus wherein a) part or all of one or more vaccinia nucleotide sequences causing immunosuppression are deleted from the viral genome; and/or b) one or more of said vaccinia nucleotide sequences causing immunosuppression is inactivated by mutation or the insertion of foreign DNA; and/or c) one or more of said vaccinia nucleotide sequences causing immunosuppression is changed to alter the function of a protein product encoded by said nucleotide sequence; which nucleotide sequences are sequences designated herein as i) Sal F 3R, ii) Sal F 9R, iii) Sal F 13R, iv) B5R, v) Sal F.15R.
- vaccinia nucleotide sequence may be the sequence designated herein as Sal F 3R.
- the vaccinia virus comprises a DNA sequence encoding a heterologous polypeptide which potentiates the immune response
- the DNA sequence may encode CD23.
- the recombinant vaccinia vectors of the present invention may be used as immunogens for the production of monoclonal and polyclonal antibodies or T-cells with specificity for heterologous peptides encoded by DNA sequences ligated into the viral genome.
- the invention also provides the monoclonal antibodies, polyclonal antibodies, .antisera and/or T cells obtained by use of the recombinant vaccinia vectors provided.
- the antibodies produced by use of the recombinant virus vectors hereof can be used in diagnostic tests and procedures, for example in detecting the antigen in a clinical sample; and they can also be used therapeutically or prophylactically for administration by way of passive immunisation.
- diagnostic test kits comprising monoclonal antibodies, polyclonal antibodies, antisera and/or T cells obtained by use of the recombinant vaccinia vectors provided.
- vaccines and medicaments which comprise a recombinant vaccinia virus hereof. These may have enhanced safety and immunogenicity over current vaccinia virus strains for the reasons indicated.
- polypeptide encoded by a nucleotide sequence selected from those defined above and alleles and variants of said polypeptides may be encoded by the nucleotide sequence designated herein as Sal F 13R and which has activity as a DNA ligase.
- the invention also includes sub-genomic DNA sequences encoding such a polypeptide, recombinant cloning and expression vectors containing such DNA, recombinant microorganisms and cell cultures capable of producing such a polypeptide.
- the invention also provides a method of attenuating a vaccinia virus vector which comprises: a) deleting part or all of one or more of the following nucleotide sequences from the viral genome; and/or b) inactivating one or more of said nucleotide sequences by mutating said nucleotide sequences or by inserting foreign DNA; and/or c) changing said one or more nucleotide sequences to alter the function of a protein product encoded by said nucleotide sequence; which nucleotide sequences are sequences designated herein as: i) Sal F 3R, ii) Sal F 9R, iii) Sal F 13R, iv) B5R, v) Sal F 15R.
- the invention also provides a method which comprises using a vaccinia virus vector as defined herein to prepare a vaccine or a medicament.
- the invention also provides the use of part or all of the nucleotide sequence designated herein as Sal F 13R or part or all of the amino acid sequence encoded by said nucleotide sequence in the identification of polypeptides with activity as a DNA ligase.
- the polypeptide represented by the amino acid sequence 7625 to 9280 (inclusive) of Fig. 11 hereof, or an allele or variant thereof may be used as an enzyme in the manipulation of DNA in recombinant technology.
- Figure 1 shows the location and direction of transcription of DNA ligase gene within the vaccinia virus genome.
- A Vaccinia virus Hindlll restriction map.
- B The 13.4 kb Sail F restriction fragment is expanded and the positions of EcoRI(E) Smal(S) restriction sites are indicated.
- CA 3300bp EcoRI - S al fragment is expanded showing the position of the DNA ligase gene (arrow), and the positions of EcoRI(E), Clal(C), Bell(Be), BglII(B) and Smal(S) restriction sites;
- Figure 2 shows the location and direction of transcription of a thymidylate kinase gene within the vaccinia virus genome.
- A Hind III restriction map.
- B Expanded 13.4 kb Sail F fragment with the position of Sail F 13R (0RF13) shown as filled box.
- C Expanded 2.4 kb Dra I fragment with position and direction of transcription of 0RF13 shown. The scale refers to this fragment. Letters in B and C indicate restriction enzyme sites: EcoRI(E), Dral(D), BamHI (B) and BclI(BC).
- Figure 3 shows the nucleotide sequence of a 1776 nucleotide region of the 13.4 kb Sail F fragment. The deduced sequence of a 552 amino acid open reading frame is shown. The open reading frame is designated Sal F 15R;
- Figure 4 shows the nucleotide sequence of 800 bp region of the vaccinia virus Sail F fragment.
- the deduced amino acid sequence of a 227 amino acid open reading frame designated Sal F 13R is shown. Numbers on the upper and lower lines refer to amino acids from the.beginning of the ORF or to the nucleotides from start of DNA fragment, respectively.
- Underlined nucleotides represent potential early transcriptional termination sequences and asterisks represent the 5' ends of early mRNA determined by SI nuclease protection.
- Figure 5 shows the nucleotide sequence and amino acid sequence for the gene Sal F 3R
- Figure 6 shows the amino acid sequence homology between the protein encoded by gene Sal F 3R and i) the human low affinity Fc receptor for IgE, (huFcR(IgE) ); ii) the antifreeze polypeptide (ANP) from Hemitripterus americans; and iii) a lectin (LEC) from Megabalanus rosa;
- Figure 7 shows the construction of plasmid pSAD3G for the deletion of Sal F 3R from the virus genome;
- Figure 8 shows a Southern blot analysis of virus vSAD3.
- Virus DNA was extracted from purified WT or vSAD3 virus and digested with Spel. DNA fragments were resolved on an agarose gel, transferred to nitrocellulose and probed with a radio-labelled DNA fragment from the Ecogpt gene. The band of 7 kb is as predicted and there is no hybridization with DNA from WT virus;
- Figure 9 shows a Northern blot of mRNA from mock- infected (lane 1) or WT virus-infected cells early (lane 3) or late (lane 2) after infection. RNAs were resolved on an agarose gel transferred to nitrocellulose and probed with a sijigle stranded, radio-labelled DNA fragment complementary only to the Sal F 3R open reading frame; Figure 10 shows the nucleotide and amino acid sequence for the gene Sal F 9R;
- Figure 11 shows the amino acid sequence homology between the protein encoded by gene Sal F 9R (Sail F 0RF9) and i) cow; and ii) human, superoxide dismutase (SOD) (Cu- Zn) proteins;
- Figure 12 shows the amino acid sequence homology between the protein encoded by gene Sal F 13R and yeast thymidylate kinase (TmpK);
- Figure 13 shows aligned amino acid sequences of vaccinia virus Sal F 13R (W) and Saccharomyces cerevisiae (SC) TmpK. Identical amino acid residues are boxed. Numbers above or below the aligned sequences refer to amino acid positions of W or SC respectively;
- Figure 14 shows : A. the aligned amino acid sequences for the presumed ATP binding site of vaccinia (W) and Saccharomyces cerevisiae (SC) TmpK, HSV TK/TmpK and human and W TK. Residues identical in all 5 sequences are boxed. Numbers indicate the amino acids between the amino terminus and the region shown; and B.
- Figure 15 shows the biochemical pathway of dTTP synthesis in which thymidylate kinase is active
- Figure 16 shows the construction of plasmids pACVl and pACV2;
- Figure 17 shows a Southern blot analyses of viruses vACHB and vACl.
- Virus DNA was extracted from purified WT, vACl or vACHB viruses and digested with Sail. DNA fragments were resolved on an agarose gel, transferred to nitrocellulose and probed with a radio-labelled DNA fragment from entirely within the TmpK gene. Sail digest gives a 13.4kb band with WT virus but bands of 8.8 and 6.7 kb for recombinants VACHB and VACl (due to an extra Sail site introduced at 3' end of Ecogpt cassette);
- Figure 18 shows the nucleotide and amino acid sequence for the gene B5R
- Figure 19 shows the amino acid sequence homology between the protein encoded by gene B5R (Sail G ORF10) and i) coagulation factor XIII B chain (F13 B); ii) complement factor H precursor (CFAH); iii) complement C2 precursor (C02); and iv) complement C4B-binding protein precursor (C4BP);
- Figure 20 shows the hydrophobicity profiles for B5R (Sail G ORF10) and H3C 28K proteins
- Figure 21 shows Northern blot of mRNA from virus infected cells early (E) or late (L) during infection. RNAs were resolved on an agarose gel transferred to nitrocellulose and probed with a single stranded, radio- labelled, DNA fragment complementary only to the B5R gene. The position of molecular weight size markers is shown in kb;
- Figure 22 shows the amino acid sequence homology between the vaccinia virus (W) protein encoded by gene Sal F 15R and amino acid sequences of yeast DNA ligases from S.pombe (sp) and S.cerevisiae (sc) made using programme MULTALIGN;
- Figure 23 shows the identification of vaccinia virus DNA ligase protein.
- Crude extracts were prepared from mock infected or vaccinia virus infected (100 pfu/cell) CV1 cells by Dounce homogenisation in 100 mM NaCl buffer as described in Kerr and Smith.
- Vaccinia virus infected early (lane 2), late (lane 3) or mock infected (lane 1) CV1 cell extracts and purified calf thymus DNA ligase I (a gift from T. Lindahl) (lane 5) were incubated with ⁇ -( 32 P) ATP (Methods). Reactions were terminated by trichloroacetic acid and covalently labelled polypeptides analysed by SDS PAGE on a 12.5% gel;
- Figure 24 shows the 61 kD polypeptide is a DNA ligase.
- Preparations of calf thymus DNA ligase (a gift from T.Lindahl, ICRF) (lane 1) and bacteriophage T4 DNA ligase (New England Biolabs) (lane 2) were labelled in parallel.
- the vaccinia sample was divided into four equal parts. One part was analysed without further manipulation (lane 3) and the remainder centrifuged through a column to remove unincorporated ATP as described in (25) except that Sephadex-G25 was used.
- Lanes 5, 6 and 7 represent the supernatant fractions from early, mock and late samples respectively after Dounce homogenisation and centrifugation at 10K for 20 minutes.
- Lanes 8, 9 and 10 are the pellet fractions from early, mock and late samples. An autoradiograph of the dried gel is shown;
- Figure 26 shows: A. Immune-precipitation of ( 35 S)- methionine labelled polypeptides from vaccinia virus infected cells. TK cells infected with vaccinia virus (30 pfu/cell) or mock infected were labelled with ( 35 S)- methionine . 1.5 - 4h post infection. Cell extracts were prepared ad immune-precipitated with pEX LIG antiserum (Kerr and Smith 1989). Lane 1 represents uninfected cells and lane 2 vaccinia virus infected cells. Molecular weight markers are shown to the right of the gel; and B. Co- migration of ( 35 S)-methionine and ⁇ -( 32 P)-ATP labelled proteins.
- Figure 27 shows immune-precipitation of labelled vaccinia virus DNA ligase.
- Calf thymus DNA ligase (lane 1 ), T4 DNA ligase (lane 2) and a phosphocellulose column fraction from vaccinia virus infected cells (lane 3) were incubated with ⁇ -( 32 P)-ATP (Kerr and Smith 1989).
- Each sample was divided into four equal parts and either analysed directly by TCA precipitation and SDS-PAGE (lanes 1, 2 and 3) or, in the case of extract from vaccinia virus infected cells, immune-precipitated with either pre-immune serum (lane 4), pEX LIG serum (lane 5) or a non-specific pEX immune serum (lane 6), followed by SDS-PAGE;
- Figure 28 shows the cloning of the vaccinia virus DNA ligase gene by PCR to form plasmid pSK17;
- Figure 29 shows the expression of the DNA ligase gene in E.coli.
- Bacterial cultures containing plasmid psK18 were inbucated for 0, 1, 2 or 4 hours after addition of IPTG and the total bacterial protein run on a polyacrylamide gel.
- the DNA ligase protein appears as a 63 kDa protein; (iii) the cell extracts shown in Figure 4b(i) were incubated with alpha-labelled 32 P-ATP and run on a p ⁇ lyacrylamide gel and an autoradiograph produced. The DNA ligase binds AMP and appears as a 63 kDa protein;
- Figure 30 shows a Southern blot of virus DNAs from viruses derived from cells infected with WT vaccinia virus and transfected with pSK14. DNA was digested with Sail, run on an agarose gel and probed with the region of the DNA ligase gene deleted from pSK14. Isolates 3, 6, 7 and 8 lack the DNA ligase sequence but replicate efficiently in tissue culture; and
- Figure 31 shows covalent binding of alpha-labelled 3 P- ATP to extracts of cells infected with viruses 1, 5, 7 and 8 described in Figure 30.
- Viruses 7 and 8 lack a DNA ligase protein consistent with the lack of DNA for the gene product shown in Figure 30. DESCRIPTION OF EMBODIMENTS
- the 13.4 kb Sail F fragment of vaccinia virus was isolated from cosmid 6, which contains virus DNA derived from a rifampicin resistant mutant (Baldick, C.J. & Moss, B. (1987) Virology 156, 138- 145), and was cloned into Sail cut pUC13 to form plasmid pSall F.
- the Sail fragment was separated from plasmid sequences and self-ligated with T4 DNA ligase. Circular molecules were randomly sheared by sonication, end-repaired with T4 DNA polymerase and Klenow enzyme and fragments of greater than 300 nucleotides cloned into Smal cut M13mpl8.
- Single stranded DNA was prepared and sequenced using the dideoxynucleotide chain termination method (Sanger, F. , Nicklen, S. & Coulson, A.R. (1977) Proc. Natl. Acad. Sci. USA, 74, 5463-5467), using [ 35 S]-dATP and buffer gradient polyacrylamide gels (Biggin, M.D., Gibson, T.J. & Hong, G.F. (1983), Proc. Natl. Acad. Sci. USA, 80, 3693-3695). For further details see (Bankier, A.T., Western, K.M. & Barrell, B.G. (1987) in Wu R. (ed. ) Methods in Enzymology 155, 51-93. Academic Press, London). The 12.6 Sail G fragment was similarly treated. Computer analysis
- Nucleotide sequence data were read from autoradiographs by sonic digitiser and assembled into contiguous sequences using programmes DBAUTO and DBUTIL (Staden, R. (1980) Nucleic Acids Res. 8, 3673-3694; Staden, R. (1982) Nucleic Acids Res. 10, 4731-4751) on a VAX 8350 computer.
- the consensus sequence was translated in 6 frames using programmes ORFFILE and DELIB (M. Boursnell, Institute of Animal Health, Houghton, UK.). Open reading frames were compared against SWISSPROT protein database and against the applicants own database of vaccinia amino acid sequences using programme FASTP (Lipman, D.J. & Pearson, W.R.
- Genes are named by (i) the restriction fragment from which they derive (i.e. SalF means Sail F fragment, or B means Hindlll B fragmen ), (ii) the number of the open reading frame initiating within the restriction fragment starting from j the left end and (iii) the direction of transcription leftwards (L) or rightwards (R).
- SalF means Sail F fragment
- B means Hindlll B fragmen
- the nucleotide sequence and deduced amino acid sequence of the gene designated Sal F 3R is shown in Figure 5.
- the single letter code is used for the designation of amino acids.
- the coding region of the gene maps between nucleotides 595 and 1071 from the left end of the Sail F fragment.
- the molecular weight of the primary translation product is predicted to be 18.1 kiloDaltons (kD).
- Near the carboxy terminus there are three potential N-linked glycosylation sites, indicating that the mature gene product is a glycoprotein.
- ⁇ Sal F 3R shows sequence homology with the amino acid sequence of the human low affinity Fc receptor for IgE (Kitutani, H. et al. (1986), Cell, 47, 657), the amino acid sequence of an antifreeze polypeptide from Hemitripterus americans (see Ng, N.F. et al, (1986), J. Biol. Chem. , 261, 15690-5) (5) and the amino acid sequence of a lectin from Megabalanus rosa (acorn barnacle) (Maramoto, K. & Kamiya, H. (1986), Biochem. ' Biophys. Acta., 874, 285-295.).
- Sal F 3R has a 26.1% amino acid identity over a 92 amino acid region of the human low affinity Fc receptor (FcR) for IgE, 22.4% amino acid identity over a 98 amino acid region of the antifreeze polypeptide from Hemitripterus americans, and a 27.0% amino acid identity over a 63 amino acid region of the lectin from Megabalanus rosa.
- FcR human low affinity Fc receptor
- the homologies suggest that the protein encoded by the Sal F 3R functions as a lectin or as a homologue of the human low affinity FcR for IgE.
- the latter homology is particularly important, as the human low affinity FcR for IgE is the same as CD23, a cell surface protein expressed on B lymphocytes which is of central importance in regulating B cell growth (Gordon, J. & Guy G.R. (1987), Immunol. Today, 8, 339).
- the vaccinia virus protein encoded by Sal F 3R is thought to function as an agonist of the normal CD23 molecule, to restrict the growth and/or differentiation of B cells and thereby reduce the host immune response to infection by the virus. Therefore, deletion of this gene from the virus genome would enhance the host immune response to the virus. The consequence of this could be restriction of virus growth and hence attenuation. It is also possible that the immune response to foreign proteins expressed by recombinant vaccinia viruses lacking this gene would be enhanced and the efficacy of such candidate vaccines improved.
- a mutant virus with the coding region of this gene interrupted and partially deleted has been constructed.
- a plasmid, pPROF was constructed by the ligation of the leftmost 3524 bp (Sall-EcoRI DNA fragment) of the vaccinia virus Sail F fragment into pUC13 that had been digested with EcoRI and Sail. This plasmid contains the entire coding region of Sal F 3R and was digested with Nsil, which cuts twice only, within the coding sequence ( Figure 7).
- the digested DNA was treated with bacteriophage T4 DNA polymerase to create blunt ends, and the larger of the two fragments was purified by agarose gel electrophoresis.
- This fragment was ligated with a gel-purified DNA fragment containing the E.coli xanthine guanine phosphoribosyl transferase (Ecogpt) gene joined to the vaccinia virus 7.5K promoter sequence.
- Ecogpt E.coli xanthine guanine phosphoribosyl transferase
- the latter fragment was obtained by digestion of plasmid pGpt07/14 (Boyle, D.B. and Coupar, B.E. H.
- Plasmid pSAD3G was transfected into CV-1 cells that were infected with wild type (WT) vaccinia virus and the virus progeny derived from these cells after 48 hours at 37°C were then plated on fresh CV-1 cells in the presence of mycophenolic acid (MPA), xanthine and hypoxanthine. These drugs permit the replication only of recombinant viruses which contain and express the Ecogpt gene (Boyle & Coupar 1988 supra; Falkner & Moss, J. Virol, j52, 1849- 54, 1988). After three rounds of plaque purification, the virus was amplified in larger cultures of CV-1 cells.
- a single-stranded radio- labelled DNA probe complementary only to the coding strand of Sal F 3R detected an early mRNA species of about 600 nucleotides. Late during infection, this mRNA was replaced by some RNA species of heterogeneous length which appear as a smear on the Northern blot. Due to the heterogeneous length,of late vaccinia virus mRNA, it is possible that this represents either mRNA initiating from the Sal F 3R promoter or from further upstream. This data allows the conclusion that the gene Sal F 3R is certainly transcribed early and possibly also late during infection.
- Sal F 9R The nucleotide and amino acid sequence of this gene is shown in Figure 10.
- the coding* region of the gene resides between nucleotides 4447 and 4821 from the left end of the Sail F fragment.
- the encoded protein has a predicted molecular weight of 13.6kD.
- Figu e 11 shows the amino acid sequence homology between the protein encoded by gene Sal F 9R and two superoxide .
- the protein encoded by Sail F ORF9 has a 36.8% amino acid identity over a 57 amino acid region of bovine superoxide dismutase, and a 37.3% amino acid identity over a 59 amino acid region of human superoxide dismutase.
- Superoxide dismutase is an enzyme that converts toxic oxidative free radicals (0 2 " ) into oxygen and hydrogen peroxide. Following engulfment of microorganisms, phagocytic cells undergo an oxidative burst which produces 0 2 ⁇ to cause destruction of the microorganism.
- African Swine Fever Virus is a likely candidate to contain this enzyme as it replicates efficiently in swine macrophages. Deletion of this gene from the viruses containing the identified gene sequence and which retain superoxide dismutase enzyme activity would result in virus attenuation due to.a reduced ability of the virus to replicate within, and be disseminated by, macrophages.
- Figure 4 shows the deduced sequence of the 227 amino acid ORF designated Sal F 13R.
- Figure 2 shows the position of Sail F 0RF13 within the vaccinia virus genome.
- TTTTTGT and TTTTTAT represent termination signals for early transcription (Yuen, L. and Moss, B. (1987) Proc. Natl. Acad. Sci. USA., 84, 6417-6421).
- the next downstream T 5 NT motif is located a further 540 nucleotides away within the promoter region of the DNA ligase gene and contains two overlapping termination signals within the sequence TTTTTTTAT.
- the deduced amino acid sequence of Sal F 13R was compared against protein database SWISSPROT and our own database of vaccinia virus proteins using programme FASTP (Lipman, D.J. and Pearson, W.R. (1985) Science, 227, 1435- 1441). No strong matches were found against other vaccinia proteins but the deduced amino acid sequence of SalF 13R had a high FASTP homology score (371) against thymidylate kinase (TmpK) of Saccharomyces cerevisiae (Jong, A.Y.S., Kuo, C.L. and Campbell, J.L. (1984) J. Biol. Chem., 259, 11052-11059; Rothstein, R., Helms, C and Rosenberg, N. (1987) Mol. Cell Biol. 7, 1198-1207).
- FASTP thymidylate kinase
- Figure 12 shows the amino acid sequence homology between the protein encoded by gene Sal F 13R and thymidylate kinase (TmpK) from yeast (Jong et al, (1984), J. Biol. Chem. 259, 11052-9).
- the two proteins share 42% amino acid identity over a 200 amino acid region and there are many additional conservative changes.
- the aligned amino acid sequences are very similar in length, (yeast 216 amino acids versus vaccinia virus 204 amino acids), and are almost colinear.
- An alignment of the two amino acid sequences is shown in Figure 13 with identical amino acids boxed.
- Amino acids residues 11-18 of the putative vaccinia TmpK enzyme fit the consensus motif for ATP binding proteins GxxGxGKS/T (Otsuka, M. and Kit, S. (1984) Virology, 135, 316-330) except for the second glycine, where there is lysine.
- An alignment of this region with the presumed ATP binding sites of yeast TmpK Jong, A.Y.S., Kuo, C.L. and Campbell, J.L. (1984) J. Biol. Chem., 259, 11052-11059; Rothstein, R., Helms, C. and Rosenberg, N. (1987) Mol. Cell Biol.
- HSV thymidine kinase (TK) TmpK HSV thymidine kinase (TK) TmpK (Otsuka, M. and Kitt, S. (1984) Virology, 135, 316-330; McKnight, S.L. (1980) Nucleic Acids Res. 8, 5949- 5964; Wagner, M.J. Sharp, J.A. and Summers, W.C. (1981) Proc. Natl. Acad. Sci. USA., 78, 1441-1445; Gompels, U. and Minson, A.C. (1986) Virology, 153, 23-247; Darby, C, Larder, B.A. and Inglis, M.M. (1986) J. Gen.
- TK thymidine kinase
- TK/TmpK contains the second glycine of the ATP binding site consensus (above).
- HSV herpes simplex virus
- the alignment of this region also shows that the highly homologous yeast and vaccinia TmpK sequences and the more divergent HSV TK/TmpK, differ from TK sequences, of which vaccinia and man are representative examples, in several respects.
- TK has been mapped and sequenced. It is a nonessential gene for in vitro replication and has been widely used as a site for insertion of foreign DNA into recombinant vaccinia viruses (Mackett, M. and Smith. G.L. (1986) J. Gen. Virol. 67, 2067-2082). It is also a determinant of virus pathogenicity for both vaccinia (Buller, R.M.L., Smith. G.L., Cremer, K., Notkins, A.L. and Moss. B. (1985) Nature, 317, 813-815) and HSV (Field, H.J. and Wildy, P. (1978) J. Hyg. Camb.
- Vaccinia virus encodes a separate enzyme, thymidine kinase (TK) that acts to convert thymidine into thymidine monophosphate in the first part of this pathway.
- TK thymidine kinase
- Two vaccinia virus mutants have been constructed in which the Sal F 13R gene has been inactivated.
- the Ecogpt gene joined to the vaccinia virus promoter p7.5K was inserted into a region of the TmpK gene predicted to be involved in nucleoside/nucleotide binding and, therefore, likely to be essential for enzyme activity (Smith et al. Nucleic Acids Res. , 17, 7581, (1989)).
- the strategy followed that described above for the Sal F 13R gene ( Figure 16).
- a plasmid, pACVl was constructed by the ligation of a 2392 bp Dral DNA fragment, derived by Dral digestion of the Sail F fragment, into Smal cut pUC13.
- pACVl contains the entire Sal F 13R coding sequence and was digested with restriction enzyme Mlul which cuts pACVl only once and within the coding region of TmpK.
- the Ecogpt gene joined to the vaccinia virus promoter p7.5K was isolated as an EcoRI fragment (as above), made blunt-ended by treatment with DNA polymerase (Klenow fragment), and ligated with pACVl that had been digested with Mlul.
- the resultant plasmid, pACV2 contained the TmpK gene interrupted by Ecogpt. The procedure is outlined in Figure 16.
- This plasmid was used to transfect CV-1 cells infected with either WT vaccinia virus or a TK" recombinant virus which expresses the hepatitis B virus surface antigen gene (Smith et al., Nature 302, 490-5, 1983).
- Recombinant viruses expressing the Ecogpt gene were selected by plaque assay in the presence of MPA and stocks grown.
- the virus derived from WT virus was called vACl and the virus derived from vHBs4 was called vACHB.
- Their genomic DNAs were analysed by Southern blotting ( Figure 17).
- SI nuclease mapping precisely located the 5' end of the early mRNA to just upstream of the second inframe ATG codon. This is roughly 65 nucleotides downstream of the first ATG codon and the protein is therefore 23 amino acids shorter than that previously predicted. (Smith et al., Nucl. Acids Res. 17, 7581-90). Assays for TmpK. activity in vaccinia virus-infected cells have been performed and enzyme activity has been detected. .
- the assays consist of incubating extracts of mock or virus-infected cells with tritiated thymidylate, resolving the reaction products by thin layer chromatography (TLC) (to separate TMP, TDT and TTP) and counting the areas of the tritium in TLC corresponding to these compounds (Jong et al., J.B.C. 259, 11052-9 (1984).
- TLC thin layer chromatography
- TmpK is an essential cellular enzyme
- the applicants have not yet demonstrated a difference between the endogenous activity in uninfected cells and that present in vaccinia virus-infected cells.
- PCR polymerase chain reaction
- the plasmid is used to complement a yeast mutant, CDC8, that is deficient in TmpK activity (Jong et al 1984).
- CDC8 yeast mutant
- the nucleotide and amino acid sequence of gene B5R are shown in Figure 18.
- the encoded protein has a predicted molecular weight of 35.1 kD and its coding region maps between nucleotides 6654 and 7604 from the left end of the Sail G fragment.
- the protein .contains hydrophobic amino acid sequences near the amino- and carboxy-termini, indicating that the protein associates with cell membranes of the infected cell or virus particle. There are also three potential sites for N-linked glycosylation indicating the mature product is a glycoprotein.
- the protein encoded by B5R has a 27.2% amino acid identity with a 246 amino acid region of coagulation factor XIII B chain, a 27.2% amino acid identity with a 125 amino acid region of complement factor H precursor, a 26.4% amino acid identity with a 178 amino acid region of complement C2 precursor, and a 24.6% amino acid identity with a 175 amino acid region of complement C4B-binding protein precursor.
- the vaccinia protein encoded by gene B5R possesses four such domains.
- Vaccinia virus contains a gene encoding another protein, H3C 28K (Kotwal, G. & Moss, B. (1988), Nature, 335, 176) which shows homology with this superfamily of complement and blood coagulation proteins and which is non- essential for virus replication.
- the protein encoded by gene B5R is related to, but distinct from, this protein, with a 29% amino acid homology.
- the H3C 28K protein is more closely related to the complement C4B-binding protein than the protein encoded by gene B5R.
- the protein encoded by gene B5R is more closely related to coagulation factor XIII than the H3C 28K protein is.
- the virus may still be attenuated by altering the gene product.
- the encoded protein binds complement factors, the region of the protein specific for the binding can be altered whilst keeping the protein functional for virus replication.
- Transcriptional analysis of the B5R gene by Northern blotting (Figure 21) showed the presence of an early mRNA of 1850 nucleotides. This size corresponds to the size of the mRNA predicted if transcription initiates just upstream of B5R and terminates 50 nucleotides downstream of the first downstream early transcription termination signal. There are also late RNAs of heterogeneous length from this region. ' SI nuclease analysis has shown that the B5R promoter is expressed both early and late during infection.
- the B5R promoter has the early RNA start site upstream of the late start site.
- the late start site maps to within a conserved motif TAAAT.
- the protein has been expressed as a fusion protein with " ⁇ -galactosidase in E.coli and is currently being expressed in the authentic form in CHO cells driven by the human cytomegalovirus immediate early promoter-enhancer.
- the vaccinia protein functions as an anti- coagulation factor it is possible that this protein, or a form from which the carboxy hydrophobic domain has been deleted, would be a useful reagent in preventing blood coagulation.
- the nucleotide and amino acid sequence of this gene are shown in Figure 3.
- the coding region of the gene maps between nucleotides 7625 and 9280 from the left end of the Sail F fragment.
- the encoded protein has a predicted molecular weight of approximately 63.3KD.
- the 5' end of the mRNA determined by primer extension maps 5 nucleotides upstream of the 5' end determined by SI nuclease protection. It is possible that there are 5' oligo-adenylate residues on this early mRNA, which hitherto have been considered solely as a characteristic of late mRNA's.
- the presumed catalytic lysine at the ATP binding site (marked with asterisk) is conserved in all these sequences as well as in T4 and T7 DNA ligases. In the E.coli enzyme, which uses NAD rather than ATP as cofactor, this site is less conserved. The most highly conserved region is very close to the carboxy terminus and is rich in basic amino acids. Over a 16 amino acid region the vaccinia protein shares identity with S. ombe at 15 positions with S.cerevisiae at 14 positions with a conservative isoleucine to valine change at one of the two divergent amino acids. This region is also well conserved in T4 with 6 identical residues and several conservative changes. The high conservation of this region suggests it plays some critical role in DNA ligase function, and its basic composition is consistent with an interaction with the DNA substrate.
- this vaccinia enzyme is the first reported primary structure of a 'mammalian' DNA ligase. It is also the only example of a eukaryotic virus encoding a DNA ligase, although other large DNA viruses which replicate in the cytoplasm, such as African Swine Fever Virus, probably encode this enzyme. Although much is known of mammalian DNA ligases, the genes encoding these enzymes have not been mapped.
- Vaccinia virus contains two other enzymes with DNA strand sealing activity (topoisomerase and nicking-joining enzyme) and models for virus DNA replication have been proposed which do not require a conventional DNA ligase (Moyer, R.W. & Graves, R.L. (1981) Cell 27, 391-401; Baroudy, B.M., Venkatesan, S. & Moss, B. (1982) Cell 28, 315-324).
- the linear double stranded DNA genome with covalently closed hairpin ends is nicked on one strand near one, or both, terminal hairpins to provide a 3' OH from which polymerisation may initiate. Elongation proceeds around the terminal hairpin, down the linear genome and around the opposite hairpin to produce concatemeric DNA molecules by a strand displacement mechanism.
- This model does not require, but may use, lagging strand synthesis.
- Figure 23 shows that extracts from vaccinia virus infected cells contain a novel radio-labelled polypeptide of molecular weight approximately 61 kD after incubation with ⁇ -( 32 P) ATP. This activity is detectable in both crude and partially purified extracts, at early (lane 2) and late (lane 3) times post infection.
- the size estimated by SDS- PAGE is in good agreement with that predicted from the amino acid composition of Sal F 15R, 63 kD which would be consistent with a lack of extensive post-translational modification.
- the extent of incorporation of radioactivity is much greater than that in mock infected cells, in which only a faint band of approximately 46 kD is visible (lane 1).
- This polypeptide is also present at reduced intensity in extracts from vaccinia virus infected cells.
- the 130 kD mammalian DNA ligase I highly purified from calf thymus, is shown in lane 5. Mock infected cells contain no polypeptide which co-migrates with the 61 kD band in infected cell extracts, suggesting the appearance of this protein is a consequence of infection with vaccinia virus.
- the 61 kD polypeptide has the properties expected of a DNA ligase ( Figure 24).
- a phosphocellulose column fraction derived from extracts of vaccinia virus infected cells late in infection was incubated with ⁇ -( 32 P) ATP and then excess ATP was removed using Sephadex G-25. The excluded protein was incubated with either no addition (lane 4), DNA ligase substrate (lane 5) or sodium pyrophosphate (lane 6). The presence of DNA substrate allows the ligase reaction to proceed to completion, with a disappearance of ( 32 P)-AMP from the enzyme. Conversely, high concentrations of pyrophosphate drive the equilibrium back towards free enzyme and ATP, again with a consequent discharge of radioactivity from the polypeptide ( Figure 24). This result indicates that the 61 kD polypeptide is a DNA ligase with DNA strand joining activity.
- the ligase activity early in infection (lanes 5 and 8) is only slightly greater than the cellular activity in mock infected cells (lanes 6 and 9), but by late in infection (lanes 7 and 10) the activity is substantially higher. Extracts prepared in this low salt extraction buffer (100 mM NaCl), have an appreciable portion of the total DNA ligase activity located in the pellet fraction after centrifugation (lanes 8-10) compared to the supernatant (lanes 5-7) but an increase in the salt concentration to IM shifts the majority of the total DNA ligase activity into the soluble fraction (data not shown).
- the upper band of molecular weight approximately 61 kD on SDS-PAGE, is more intense than the lower, of approximately 54 kD.
- No protein is recognised in mock infected cells (lane 1).
- the portion of the gene inserted into the pEX LIG construct does not include the regions of strongest amino acid sequence homology with yeast DNA ligases, therefore cross-reaction with mammalian ligases might not be expected.
- Both polypeptides are early virus gene products as treatment of the cells with cytosine arabinoside, an inhibitor of DNA replication, does not affect their expression (data not* shown).
- the DNA ligase would be likely to be an essential gene if it was involved in DNA replication, in which case it would not be possible to select recombinant virus containing a specific deletion of this gene.
- An alternative approach to prove that Sal F 15R gene product was responsible for the increase DNA ligase activity in vaccinia virus infected cells was therefore chosen. This made use of the pEX LIG antiserum, raised against Sal F 15R encoded protein, in immune-precipitation experiments against the radio-labelled DNA ligase-AMP adduct.
- the pEX LIG antiserum can efficientlyprecipitate the ( 32 P)-labelled DNA ligase protein in extracts from vaccinia virus infected cells ( Figure 27, lane 5), whereas pre-immune serum from the same rabbit (lane 4), or a non-specific immune serum raised against an unrelated pEX fusion protein ' (lane 6), do not recognise the 61 kD polypeptide ( Figure 28).
- Control experiments indicate that neither purified calf thymus (lane 1) nor bacteriophage T4 DNA ligase (lane 2) can be immune-precipitated by the pEX LIG antiserum (data not shown).
- the immune-precipitation of the novel DNA ligase-AMP adduct by the antiserum raised against Sal F 15R encoded protein clearly demonstrates that this vaccinia virus gene encodes the observed DNA ligase activity.
- PCR polymerase chain reaction
- pSK16 contains the whole DNA ligase gene inserted into the Smal site of pUC13 and was constructed by the isolation of a Clal to Mlul fragment from the pSK13.
- pSK13 contains the 3.3kb EcoRI to Smal fragment of the Sail F fragment cloned into pUC13. The PCR fragment was sequenced to confirm no mutations had been introduced by PCR.
- Plasmid pSK13 was digested with Nrul (which cuts just downstream of the ligase methionine initiation codon) and Bglll (which cuts 997 bp further downstream). The overhanging ends were made blunt-ended with DNA polymerase (Klenow fragment) and the larger of the two fragments ligated with the Ecogpt gene linked to the vaccinia virus 7.5K promoter.
- a recombinant vaccinia virus vaccine for use either in vaccination programmes or for use as an immunogen in the preparation of antibodies
- the gene encoding the immunogen is isolated and introduced into the virus vector by conventional genetic engineering techniques, and the virus vector is transferred into the host, e.g. humans or animals by vaccination.
- antibodies to the immunogen are either extracted from the host antiserum (or unpurified antiserum may be used) using standard techniques well known in the art.
- Monoclonal antibodies may also be prepared from the cells of the immunised animals using standard techniques well known in the art.
- the peptides encoded by the amino acid sequences encoded by the nucleotide sequences provided may be produced using conventional genetic engineering techniques.
- the gene sequences identified also provide sites for the insertion of 'foreign' gene sequences into the vaccinia virus genome and may cause virus attenuation due to inactivation of the vaccinia genes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898907468A GB8907468D0 (en) | 1989-04-03 | 1989-04-03 | Vaccinia vectors,vaccinia genes and expression products thereof |
GB8907468.6 | 1989-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990012101A1 true WO1990012101A1 (en) | 1990-10-18 |
Family
ID=10654377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1990/000493 WO1990012101A1 (en) | 1989-04-03 | 1990-04-03 | Vaccinia vectors, vaccinia genes and expression products thereof |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0465539A1 (en) |
JP (1) | JPH04504357A (en) |
AU (1) | AU5350990A (en) |
CA (1) | CA2033200A1 (en) |
GB (1) | GB8907468D0 (en) |
WO (1) | WO1990012101A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015672A1 (en) * | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
WO1992022641A1 (en) * | 1991-06-14 | 1992-12-23 | Virogenetics Corporation | Immunodeficiency virus recombinant poxvirus vaccine |
US5364773A (en) * | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5858705A (en) * | 1995-06-05 | 1999-01-12 | Human Genome Sciences, Inc. | Polynucleotides encoding human DNA ligase III and methods of using these polynucleotides |
AT405292B (en) * | 1994-04-29 | 1999-06-25 | Immuno Ag | RECOMBINANT POXVIRUSES WITH FOREIGN DNA IN ESSENTIAL REGIONS |
US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
WO2005054451A1 (en) * | 2003-12-05 | 2005-06-16 | Hokkaido Technology Licensing Office Co., Ltd. | Highly safe smallpox vaccine virus and vaccinia virus vector |
US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU699903B2 (en) * | 1990-11-20 | 1998-12-17 | Virogenetics Corporation | Measles virus recombinant poxvirus vaccine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0255383A1 (en) * | 1986-07-31 | 1988-02-03 | Toa Nenryo Kogyo Kabushiki Kaisha | Improved mutant vaccinia virus and process for production thereof |
-
1989
- 1989-04-03 GB GB898907468A patent/GB8907468D0/en active Pending
-
1990
- 1990-04-03 AU AU53509/90A patent/AU5350990A/en not_active Abandoned
- 1990-04-03 EP EP90905571A patent/EP0465539A1/en not_active Withdrawn
- 1990-04-03 WO PCT/GB1990/000493 patent/WO1990012101A1/en not_active Application Discontinuation
- 1990-04-03 CA CA002033200A patent/CA2033200A1/en not_active Abandoned
- 1990-04-03 JP JP2505342A patent/JPH04504357A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0255383A1 (en) * | 1986-07-31 | 1988-02-03 | Toa Nenryo Kogyo Kabushiki Kaisha | Improved mutant vaccinia virus and process for production thereof |
Non-Patent Citations (3)
Title |
---|
Nucleic Acids Research, Volume 17, No. 22, 25 November 1989, S.M. KERR et al.: "Vaccinia Virus Encodes a Polypeptide with DNA Ligase Activity", pages 9039-9050 * |
Proc. Natl. Acad. Sci. USA, Volume 86, No. 4, February 1989, (Washington, D.C., US), D. RODRIQUEZ et al.: "Highly Attenuated Vaccinia Virus Mutants for the Generation of Safe Recombinant Viruses", pages 1287-1291 * |
Vaccine, Volume 5, No. 1, March 1987, (Guildford, Surrey, GB) M. MORITA et al.: "Recombinant Vaccinia Virus LC16m0 or LC16m8 that Expresses Hepatitis B Surface Antigen while Preserving the Attenuation of the Parental Virus Strain", pages 65-70 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
US5942235A (en) * | 1981-12-24 | 1999-08-24 | Health Research, Inc. | Recombinant poxvirus compositions and methods of inducing immune responses |
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US6537594B1 (en) | 1989-03-08 | 2003-03-25 | Virogenetics Corporation | Vaccina virus comprising cytokine and/or tumor associated antigen genes |
US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US7144578B2 (en) | 1990-11-20 | 2006-12-05 | Connaught Technology Corporation | Poxvirus-rabies recombinants and compositions and methods employing the recombinants |
US6265189B1 (en) | 1991-01-07 | 2001-07-24 | Virogenetics Corporation | Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen |
US5756103A (en) * | 1991-03-07 | 1998-05-26 | Virogenetics Corporation | Alvac canarypox virus recombinants comprising heterlogous inserts |
US5762938A (en) * | 1991-03-07 | 1998-06-09 | Virogenetics Corporation | Modified recombinant vaccinia virus and expression vectors thereof |
US5766599A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Trova fowl pox virus recombinants comprising heterologous inserts |
US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
WO1992015672A1 (en) * | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5494807A (en) * | 1991-03-07 | 1996-02-27 | Virogenetics Corporation | NYVAC vaccinia virus recombinants comprising heterologous inserts |
US5364773A (en) * | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
WO1992022641A1 (en) * | 1991-06-14 | 1992-12-23 | Virogenetics Corporation | Immunodeficiency virus recombinant poxvirus vaccine |
AT405292B (en) * | 1994-04-29 | 1999-06-25 | Immuno Ag | RECOMBINANT POXVIRUSES WITH FOREIGN DNA IN ESSENTIAL REGIONS |
US6284504B1 (en) | 1995-03-31 | 2001-09-04 | Human Genome Sciences, Inc. | Human DNA ligase III |
US5858705A (en) * | 1995-06-05 | 1999-01-12 | Human Genome Sciences, Inc. | Polynucleotides encoding human DNA ligase III and methods of using these polynucleotides |
US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
WO2005054451A1 (en) * | 2003-12-05 | 2005-06-16 | Hokkaido Technology Licensing Office Co., Ltd. | Highly safe smallpox vaccine virus and vaccinia virus vector |
US7638132B2 (en) | 2003-12-05 | 2009-12-29 | National University Corporation Hokkaido University | Highly safe smallpox vaccine virus and vaccinia virus vector |
Also Published As
Publication number | Publication date |
---|---|
JPH04504357A (en) | 1992-08-06 |
AU5350990A (en) | 1990-11-05 |
EP0465539A1 (en) | 1992-01-15 |
CA2033200A1 (en) | 1990-10-04 |
GB8907468D0 (en) | 1989-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU595190B2 (en) | A transcriptional regulatory sequence from the 5'flanking region of the vaccinia virus | |
US6130066A (en) | Vectors having enhanced expression and methods of making and uses thereof | |
JP3044062B2 (en) | Recombinant poxvirus host selection system | |
EP0353851B1 (en) | Fowlpox virus non-essential regions | |
Hirt et al. | Localization and fine structure of a vaccinia virus gene encoding an envelope antigen | |
Bertholet et al. | One hundred base pairs of 5'flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription. | |
US5182210A (en) | Fowlpox virus promoters | |
Niles et al. | Vaccinia virus gene D8 encodes a virion transmembrane protein | |
Auperin et al. | Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection | |
US5032520A (en) | DNA sequences encoding infectious bronchitis virus spike protein | |
US20030013076A1 (en) | Parapoxvirus vectors | |
JP2003310286A (en) | Poxvirus-based expression vector containing heterologous insertion part induced from lentivirus | |
CA2110489A1 (en) | Immunodeficiency virus recombinant poxvirus vaccine | |
DK175533B1 (en) | Vaccine against rabies and its method of preparation | |
JPH084508B2 (en) | Recombinant vaccinia virus | |
Colinas et al. | Extrachromosomal recombination in vaccinia-infected cells requires a functional DNA polymerase participating at a level other than DNA replication | |
Wittek et al. | Mapping of the genes coding for the two major vaccinia virus core polypeptides | |
WO1990012101A1 (en) | Vaccinia vectors, vaccinia genes and expression products thereof | |
WO1992007944A1 (en) | Vaccinia vectors, vaccinia genes and expression products thereof | |
Weir et al. | Use of a bacterial expression vector to identify the gene encoding a major core protein of vaccinia virus | |
WO1994012617A1 (en) | Hepatitis b virus vaccines | |
Gong et al. | A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus | |
EP0330781B1 (en) | Vaccine against rinderpest virus using recombinant vaccinia virus | |
CA2104649A1 (en) | Antisense compounds complementary to hcv genome | |
Cranmer et al. | Cloning, characterization, and expression of the murine cytomegalovirus homologue of the human cytomegalovirus 28-kDa matrix phosphoprotein (UL99) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA GB JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2033200 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990905571 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990905571 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990905571 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: CA Ref document number: 2033200 Kind code of ref document: A Format of ref document f/p: F |